Last checked at 4 Sep 2014 07:00
4 September 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Shareholder update
Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2014 on the 4 September 2014. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.
Balance Sheet as at 31 March 2014
£ '000 | |
Total Non-Current Assets | 14,426 |
Total Current Assets | 18,219 |
Total Current Liabilities | (5,339) |
Total Non-Current Liabilities | (6,436) |
Total Equity | 20,870 |
Consolidated Income Statement for the 6 months ended 31 March 2014
£'000 | |
Revenue | 27,426 |
Profit after tax for the period | 5,503 |
Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel / Clare Terlouw | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Victoria Foster Mitchell / Mo Noonan |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with expected revenue of £45.7million, before milestones and rebates and supported by a foreign exchange benefit of £2.3million, an increase of 14% on the previous year (2013:£39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.